Non-mucosal vaccination strategies to enhance mucosal immunity
- PMID: 37881504
- PMCID: PMC10599649
- DOI: 10.18609/vac.2023.034
Non-mucosal vaccination strategies to enhance mucosal immunity
Abstract
The SARS-CoV-2 pandemic has highlighted the need for improved vaccines that can elicit long-lasting mucosal immunity. Although mucosal delivery of vaccines represents a plausible method to enhance mucosal immunity, recent studies utilizing intradermal vaccine delivery or incorporation of unique adjuvants suggest that mucosal immunity may be achieved by vaccination via non-mucosal routes. In this expert insight, we highlight emerging evidence from pre-clinical studies that warrant further mechanistic investigation to improve next-generation vaccines against mucosal pathogens, especially those with pandemic potential.
Conflict of interest statement
Morici LA discloses she has the following grants/contracts (HDTRA1–19-C0013; NIH 272201800045C; NIH/NIAID R01 AI166756–01). She receives consulting fees and payment for expert testimony from AP Experts LLC. McLachlan JB discloses he has the following grant/contract (NIH 01AI166756). Lastly, Tulane has an issued patent on vaccine adjuvant technology for which Morici LA and McLachlan JB are inventors.AUTHORSHIP & CONFLICT OF INTEREST
References
-
- Liu L, Johnson HL, Cousens S, Perin J, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379(9832), 2151–2161. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous